STRO stock forecast, quote, news & analysis
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company... Show more
Why Sutro Biopharma (STRO) Stock Is Down -32% in the Last 30 Days
Key Takeaways
- Sutro Biopharma (STRO) shares fell roughly 32% over the last 30 days, from a closing price of $16.35 to around $11.14.
- The decline extends a broader multi-month downtrend, with the stock down more than 50% over the past three months.
- Pressure traces back to August second-quarter 2026 results and an early STRO-004 Phase 1 update that left investors seeking more complete efficacy detail; quarterly revenue fell about 85% year over year.
- The next major readouts are the full STRO-004 (STRIVE-01) study update targeted for the first half of 2027 and third-quarter earnings expected in early November 2026.
- Some analysts view the STRO-004 selloff as an overreaction, though broader sentiment has cooled amid a thinner near-term catalyst calendar.
Sutro Biopharma (STRO) Company Overview and Market Position
Sutro Biopharma, Inc. is a clinical-stage oncology company headquartered in South San Francisco, California. The company develops next-generation antibody-drug conjugates (ADCs) using its proprietary cell-free protein synthesis platform, XpressCF, and its site-specific conjugation technology. This approach lets Sutro optimize the antibody, linker, and payload components of an ADC to improve drug exposure, reduce side effects, and expand the range of treatable tumor types.
Sutro's wholly owned pipeline is led by STRO-004, a Tissue Factor-targeting exatecan ADC in a Phase 1 trial, followed by STRO-006 (an integrin beta-6-targeting ADC) and STRO-227 (a PTK7-targeting dual-payload ADC). The company also maintains research and development collaborations, including with Astellas Pharma, and its technology platform previously supported the creation of vaccine developer Vaxcyte (PCVX). Investors follow the stock for its differentiated ADC platform, its dual-payload innovation, and the clinical progress of its lead programs.
Sutro Biopharma (STRO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, STRO declined from a closing price of $16.35 to approximately $11.14, a drop of about 32%. The move was not a single-day event but a steady grind lower punctuated by sharper selloffs in mid-October, when the stock reached six-month lows.
The picture is even weaker over the last quarter. From levels around $23 in mid-July, the shares have fallen more than 50%. The stock entered July near $30 before sliding through a series of lower highs and lower lows, reflecting a persistent risk-off tone that has outweighed the company's cash runway and pipeline milestones.
What Drove STRO Stock Price in the Last 30 Days
The 30-day decline is best understood as the continuation of a selloff that began in mid-August. The central catalyst was the August 12 second-quarter 2026 report, in which Sutro posted revenue of $9.8 million — down roughly 85% year over year — and a net loss of $38.5 million, or $2.33 per share, missing consensus estimates. The quarter's revenue reflected a difficult comparison against the prior-year period, which had benefited from one-time collaboration-related revenue.
Alongside earnings, Sutro provided an early update from the Phase 1 STRIVE-01 study of STRO-004, reporting confirmed and ongoing unconfirmed partial responses across pancreatic, head and neck, and non-small cell lung cancers, together with a favorable tolerability profile. However, investors had expected a more complete efficacy dataset, and the absence of patient-level detail on the magnitude and durability of responses drove a sharp repricing. H.C. Wainwright characterized the decline as "an overreaction" to limited data and reiterated a Buy rating with a $50 price target.
With the next substantive STRO-004 readout not expected until the first half of 2027, the stock has lacked a near-term catalyst to arrest the slide, leaving it vulnerable to continued selling through September and October.
What Drove STRO Stock Performance Over the Last Quarter
The quarterly decline reflects a shift from the optimism that carried STRO to a 52-week high of $43.85 in May 2026. Earlier in the year, the stock benefited from a February 2026 equity offering that extended the cash runway into at least the second quarter of 2028, an analyst upgrade cycle, and enthusiasm around the ADC platform.
That momentum reversed after the August earnings and data update. The limited efficacy detail for STRO-004, combined with a year-over-year revenue decline tied to fluctuating collaboration revenue, prompted a reassessment of near-term value. With key data points pushed to 2027, the shares have trended lower as the market waits for more definitive clinical evidence. Analyst price targets remain well above the current price — the consensus average target was around $49.50 — but ratings have moderated, and the stock has remained below its major moving averages.
Trending AI Robots
Investors seeking a data-driven approach to navigating volatile biotech names may find value in Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that trade thousands of tickers across a range of strategies, timeframes, and performance metrics. Only the top-performing and most relevant bots are featured in this curated section, giving traders a streamlined way to explore automated strategies without sifting through the full catalog. Because each bot differs in its methodology, risk profile, and holding period, the section is designed to help users identify approaches that match their own objectives. Those interested in exploring automated trading tools can review the currently featured bots on the Trending AI Robots page.
STRO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for STRO are clinical and financial. Investors will watch for the full STRIVE-01 study update on STRO-004, targeted for the first half of 2027, which is expected to provide a more complete picture of efficacy and durability. Nearer term, the initiation of a Phase 1 trial for STRO-006 and progress toward an investigational new drug submission for STRO-227 remain key pipeline milestones.
On the financial side, third-quarter 2026 results are expected in early November, with attention on collaboration revenue trends and cash burn. As of June 30, 2026, the company held $164.3 million in cash, cash equivalents, and marketable securities, expected to fund operations into at least the second quarter of 2028. Macroeconomic conditions, biotech sector sentiment, and any shifts in analyst ratings or price targets could also influence near-term trading. As with any clinical-stage biotechnology company, execution risk on clinical programs and the timing of future capital needs remain central considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STRO in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 49 cases where STRO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where STRO advanced for three days, in 209 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 73 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for STRO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for STRO moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.651) is normal, around the industry mean (2.973). P/E Ratio (-0.592) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology